Nature Publishing Group and Sermo partner to help physicians

Nature Publishing Group (NPG) and Sermo, the largest online physician community in the US, announced a partnership to facilitate the discussion and interpretation of content in leading NPG medical journals by US physicians.

In this collaboration, NPG will add "Discuss on Sermo" links to the online versions of articles in 12 of its leading medical journals, including Nature Medicine, Nature Clinical Practice Cardiovascular Medicine, and Leukemia. These links will allow US physicians reading the journals to create or join discussions of the articles in Sermo's physician-only knowledge-sharing community. On Sermo, discussions of research articles include both free-text comments and user-generated surveys, capturing the depth of individual observations and opinions as well as aggregating the collective wisdom of its 50,000 physician members.

To best facilitate information sharing, NPG will make the full text of all articles from a selection of its medical journals freely available to registered users of Sermo, which is itself freely available to all licensed US physicians. In return, Sermo will allow NPG to use the Sermo community to better inform and extend the relevance of its articles. The partnership is Sermo's first with a commercial publisher.

NPG's partnership with Sermo is consistent with its aims to use the Internet to improve research and communication, and its specific focus on improving medical research. "Clinical medicine is an important and growing area for Nature Publishing Group, as we continue to develop the Nature Clinical Practice series and our society-owned journal publishing program. At the same time, NPG is making efforts to bring its medical content to where the doctors are, and increasingly in the US, this is Sermo," said Steven Inchcoombe, Managing Director of NPG. "We are excited by the amount of valuable information generated in physician discussions on Sermo, and believe that bringing our medical research to physicians in this new medium will help speed the process of bringing new research advances to patient care."

"We are happy to kickoff this initiative with Nature Publishing Group, which continues to be a leader in adopting new technologies to augment its research publications,” said Alex Frost, Sermo VP for Research. "Sermo's core strength is bringing together physicians and aggregating their knowledge in a structured way. Although many have seen “user-generated” content as a threat to scholarly research and publishing, in partnering with NPG we’re realizing an important example of how user-generated content can augment and improve research and publishing."

The NPG titles that will make selected content freely available to Sermo users are: Nature Clinical Practice Cardiovascular Medicine, Nature Clinical Practice Endocrinology & Metabolism, Nature Clinical Practice Neurology, Nature Clinical Practice Urology, International Journal of Impotence Research, International Journal of Obesity, Journal of Human Hypertension, Journal of Perinatology, Leukemia, and Prostate Cancer and Prostatic Diseases. 'Discuss on Sermo' links will be added to the online versions of selected articles in these journals, and also in Nature Medicine and Nature Reviews Cancer.

About Sermo
Launched in September 2006, Sermo is already the largest online physician community in the US, with nearly 50,000 physician members. On Sermo, physicians exchange knowledge with each other and gain potentially life saving insights directly from colleagues. Sermo harnesses the power of collective wisdom and enables physicians to discuss new clinical findings, report unusual events, and work together to improve patient care. Through its unique business model, Sermo is free to physicians and has no advertising or promotion. For more information, visit www.sermo.com.

About Nature Publishing Group
Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through Nature News and scientific career information through Naturejobs.

NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Madrid, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to www.nature.com.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...